1700056E22Rik Inhibitors comprise a range of compounds that has shown to indirectly influence the function of the protein encoded by the 1700056E22Rik gene. These inhibitors target various signaling pathways and cellular processes that might be associated with the protein's function. The inhibitors operate through diverse mechanisms, including kinase inhibition, proteasome inhibition, and modulation of gene expression. Each inhibitor in this class has been chosen based on its known action on a specific cellular pathway that could be relevant to the function of 1700056E22Rik.
Developing inhibitors for a specific protein such as 1700056E22Rik requires a comprehensive understanding of the protein's role within the cell, its interactions with other proteins, and its involvement in specific pathways. The design and synthesis of these inhibitors are based on an intricate knowledge of the target pathways, employing advanced techniques like computational modeling and high-throughput screening. Subsequent experimental validation, including biochemical assays and cellular studies, is crucial to ascertain their efficacy and specificity in relation to 1700056E22Rik.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A broad-spectrum kinase inhibitor, which has shown to disrupt kinase signaling pathways involving 1700056E22Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, which has shown to impact PI3K/Akt signaling pathways potentially linked with 1700056E22Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, which has shown to influence cellular growth and autophagy pathways involving 1700056E22Rik. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
An HDAC inhibitor, which has shown to affect gene expression processes that involve 1700056E22Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An ERK pathway inhibitor, which has shown to alter signaling pathways where 1700056E22Rik is active. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, which has shown to disrupt signaling pathways involving 1700056E22Rik. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor, which has shown to influence protein degradation pathways related to 1700056E22Rik. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
A calcium channel blocker, which has shown to alter calcium signaling pathways involving 1700056E22Rik. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
An HDAC inhibitor, which has shown to alter chromatin structure and gene expression related to 1700056E22Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor, which has shown to impact signaling pathways involving 1700056E22Rik. | ||||||